- Home
- MERC vs AYTU Comparison
MERC vs AYTU Comparison
Compare MERC & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | AYTU |
|---|---|---|
| Founded | 1968 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 27.4M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MERC | AYTU |
|---|---|---|
| Price | $0.35 | $2.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.25 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 3.4M | 21.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | $27,632,080.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $10.12 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 25.50 | ★ 277.47 |
| 52 Week Low | $0.34 | $1.65 |
| 52 Week High | $2.96 | $3.07 |
Technical Indicators
Market Signals| Indicator | MERC | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 47.53 |
| Support Level | $0.35 | $2.07 |
| Resistance Level | $0.65 | $2.33 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 28.78 | 49.00 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.